MCID: XLN206
MIFTS: 32

X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

MalaCards integrated aliases for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

Name: X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome 58
Johnson Syndrome 58

Characteristics:

Orphanet epidemiological data:

58
x-linked intellectual disability-macrocephaly-macroorchidism syndrome
Inheritance: X-linked recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 33 Q87.8
Orphanet 58 ORPHA85320
SNOMED-CT via HPO 68 61152003

Summaries for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

MalaCards based summary : X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome, also known as johnson syndrome, is related to dubin-johnson syndrome and stevens-johnson syndrome/toxic epidermal necrolysis. The drugs Gabapentin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and liver, and related phenotypes are macrocephaly and macroorchidism

Related Diseases for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Diseases related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 429, show less)
# Related Disease Score Top Affiliating Genes
1 dubin-johnson syndrome 12.9
2 stevens-johnson syndrome/toxic epidermal necrolysis 12.8
3 severe cutaneous adverse reaction 12.5
4 stevens-johnson syndrome/toxic epidermal necrolysis overlap syndrome 12.4
5 erythema multiforme 12.2
6 erythema multiforme major 11.9
7 hyperbilirubinemia, rotor type 11.6
8 bilirubin metabolic disorder 11.6
9 gilbert syndrome 11.5
10 5-oxoprolinase deficiency 11.2
11 crigler-najjar syndrome, type ii 11.2
12 auditory neuropathy spectrum disorder 11.2
13 exanthem 10.7
14 conjunctivitis 10.5
15 mucositis 10.4
16 allergic hypersensitivity disease 10.4
17 cholestasis 10.4
18 yemenite deaf-blind hypopigmentation syndrome 10.4
19 lupus erythematosus 10.4
20 systemic lupus erythematosus 10.4
21 bronchiolitis 10.4
22 bronchiolitis obliterans 10.3
23 hypereosinophilic syndrome 10.3
24 keratitis, hereditary 10.3
25 skin disease 10.3
26 bullous pemphigoid 10.3
27 herpes simplex 10.3
28 stomatitis 10.3
29 respiratory failure 10.3
30 dermatitis 10.3
31 pneumonia 10.3
32 acute generalized exanthematous pustulosis 10.2
33 neutropenia 10.2
34 entropion 10.2
35 dysphagia 10.2
36 limbal stem cell deficiency 10.2
37 ocular cicatricial pemphigoid 10.2
38 acute kidney failure 10.2
39 liver disease 10.2
40 drug reaction with eosinophilia and systemic symptoms 10.2
41 autoimmune disease 10.2
42 autosomal recessive disease 10.2
43 corneal neovascularization 10.2
44 lung disease 10.2
45 cicatricial pemphigoid 10.1
46 purpura 10.1
47 endophthalmitis 10.1
48 cataract 10.1
49 fixed drug eruption 10.1
50 immune deficiency disease 10.1
51 major affective disorder 8 10.1
52 major affective disorder 9 10.1
53 graft-versus-host disease 10.1
54 drug allergy 10.1
55 dry eye syndrome 10.1
56 acute cystitis 10.1
57 diarrhea 10.1
58 bipolar disorder 10.1
59 kidney disease 10.1
60 keratoconjunctivitis 10.1
61 myeloma, multiple 10.1
62 cicatricial entropion 10.1
63 gout 10.1
64 pneumothorax 10.1
65 hepatitis 10.1
66 pharyngitis 10.1
67 keratopathy 10.1
68 liver cirrhosis 10.1
69 acquired immunodeficiency syndrome 10.1
70 chickenpox 10.1
71 bacterial conjunctivitis 10.1
72 encephalopathy 10.1
73 intrahepatic cholestasis of pregnancy 10.0
74 uveitis 10.0
75 mycoplasma pneumoniae pneumonia 10.0
76 viral hepatitis 10.0
77 pulmonary tuberculosis 10.0
78 lymphopenia 10.0
79 connective tissue disease 10.0
80 b-cell lymphoma 10.0
81 measles 10.0
82 pemphigus 10.0
83 48,xyyy 10.0
84 autoimmune progesterone dermatitis 10.0
85 hepatocellular carcinoma 10.0
86 major affective disorder 1 10.0
87 thrombocytopenic purpura, autoimmune 10.0
88 factor vii deficiency 10.0
89 dermatitis herpetiformis, familial 10.0
90 hepatitis c virus 10.0
91 variola major 10.0
92 cholelithiasis 10.0
93 bacterial infectious disease 10.0
94 acute conjunctivitis 10.0
95 disseminated intravascular coagulation 10.0
96 ornithosis 10.0
97 tetanus 10.0
98 nephrotic syndrome 10.0
99 toxic shock syndrome 10.0
100 corneal ectasia 10.0
101 rheumatic disease 10.0
102 thrombocytopenia 10.0
103 cholecystitis 10.0
104 interstitial lung disease 10.0
105 cellulitis 10.0
106 gastritis 10.0
107 bronchitis 10.0
108 corneal ulcer 10.0
109 dermatitis herpetiformis 10.0
110 vasculitis 10.0
111 smallpox 10.0
112 lichen planus 10.0
113 exfoliative dermatitis 10.0
114 bronchiolitis obliterans with obstructive pulmonary disease 10.0
115 paraneoplastic pemphigus 10.0
116 overgrowth syndrome 10.0
117 neurofibromatosis, type ii 9.9
118 pfeiffer syndrome 9.9
119 alcohol dependence 9.9
120 colorectal cancer 9.9
121 lacrimal duct defect 9.9
122 dowling-degos disease 1 9.9
123 retinal detachment 9.9
124 rheumatoid arthritis 9.9
125 trigeminal neuralgia 9.9
126 lung cancer 9.9
127 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
128 endometrial cancer 9.9
129 intraocular pressure quantitative trait locus 9.9
130 hydrops, lactic acidosis, and sideroblastic anemia 9.9
131 deficiency anemia 9.9
132 hemophagocytic lymphohistiocytosis 9.9
133 cutaneous lupus erythematosus 9.9
134 diffuse large b-cell lymphoma 9.9
135 keratoconus 9.9
136 endocarditis 9.9
137 lymphocytic leukemia 9.9
138 common cold 9.9
139 interstitial nephritis 9.9
140 cholecystolithiasis 9.9
141 pseudomembranous conjunctivitis 9.9
142 rabies 9.9
143 chlamydia 9.9
144 hemosiderosis 9.9
145 punctate epithelial keratoconjunctivitis 9.9
146 conjunctival pigmentation 9.9
147 bronchopneumonia 9.9
148 pancytopenia 9.9
149 hereditary spherocytosis 9.9
150 amenorrhea 9.9
151 ectropion 9.9
152 squamous cell carcinoma 9.9
153 cheilitis 9.9
154 vascular disease 9.9
155 hepatitis c 9.9
156 enthesopathy 9.9
157 post-traumatic stress disorder 9.9
158 chronic conjunctivitis 9.9
159 hemangioma 9.9
160 glomerulonephritis 9.9
161 mood disorder 9.9
162 mixed connective tissue disease 9.9
163 pustulosis of palm and sole 9.9
164 eye disease 9.9
165 hemolytic anemia 9.9
166 congestive heart failure 9.9
167 acute stress disorder 9.9
168 anthrax disease 9.9
169 myocarditis 9.9
170 influenza 9.9
171 arthritis 9.9
172 ulcerative colitis 9.9
173 crohn's disease 9.9
174 psoriasis 9.9
175 ritter's disease 9.9
176 hard palate cancer 9.9
177 fatty liver disease 9.9
178 bronchiectasis 9.9
179 toxoplasmosis 9.9
180 cytokine deficiency 9.9
181 dwarfism 9.9
182 granulocytopenia 9.9
183 linear iga disease 9.9
184 cytomegalovirus infection 9.9
185 seizure disorder 9.9
186 atopic keratoconjunctivitis 9.9
187 rare hereditary hemochromatosis 9.9
188 acute liver failure 9.9
189 rare surgical neurologic disease 9.9
190 aniridia 1 9.7
191 atherosclerosis susceptibility 9.7
192 breast cancer 9.7
193 centralopathic epilepsy 9.7
194 distichiasis 9.7
195 exudative vitreoretinopathy 1 9.7
196 fibrosis of extraocular muscles, congenital, 1 9.7
197 hashimoto thyroiditis 9.7
198 renal cell carcinoma, nonpapillary 9.7
199 ige responsiveness, atopic 9.7
200 migraine with or without aura 1 9.7
201 motion sickness 9.7
202 osteoporosis 9.7
203 otitis media 9.7
204 pemphigus vulgaris, familial 9.7
205 pneumothorax, primary spontaneous 9.7
206 sarcoidosis 1 9.7
207 small cell cancer of the lung 9.7
208 abetalipoproteinemia 9.7
209 diabetes mellitus, insulin-dependent 9.7
210 ectodermal dysplasia, ectrodactyly, and macular dystrophy syndrome 9.7
211 hemochromatosis, type 1 9.7
212 lymphoma, hodgkin, classic 9.7
213 hypervitaminosis a 9.7
214 cholestasis, benign recurrent intrahepatic, 1 9.7
215 ocular motor apraxia 9.7
216 wilson disease 9.7
217 adrenoleukodystrophy 9.7
218 coats disease 9.7
219 ataxia and polyneuropathy, adult-onset 9.7
220 gallbladder disease 1 9.7
221 suppression of tumorigenicity 12 9.7
222 spondylospinal thoracic dysostosis 9.7
223 astigmatism 9.7
224 macular degeneration, age-related, 1 9.7
225 dermatitis, atopic 9.7
226 lymphoma, non-hodgkin, familial 9.7
227 pars planitis 9.7
228 pulmonary disease, chronic obstructive 9.7
229 coronary heart disease 1 9.7
230 psoriatic arthritis 9.7
231 kala-azar 1 9.7
232 myocardial infarction 9.7
233 major depressive disorder 9.7
234 keratoconus 3 9.7
235 human immunodeficiency virus type 1 9.7
236 tukel syndrome 9.7
237 spondylocostal dysostosis 3, autosomal recessive 9.7
238 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
239 systemic lupus erythematosus 6 9.7
240 lung cancer susceptibility 3 9.7
241 microvascular complications of diabetes 5 9.7
242 leukemia, acute lymphoblastic 9.7
243 alpha-1-antitrypsin deficiency 9.7
244 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.7
245 infantile liver failure syndrome 1 9.7
246 leukemia, acute lymphoblastic 3 9.7
247 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
248 alkuraya-kucinskas syndrome 9.7
249 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.7
250 hepatitis, fulminant viral 9.7
251 hypertrophic scars 9.7
252 chronic ulcer of skin 9.7
253 stargardt disease 9.7
254 phenytoin allergy 9.7
255 chlamydia pneumonia 9.7
256 chikungunya 9.7
257 aspiration pneumonia 9.7
258 adult t-cell leukemia 9.7
259 lennox-gastaut syndrome 9.7
260 follicular lymphoma 9.7
261 infective endocarditis 9.7
262 sexual disorder 9.7
263 lymphoma 9.7
264 purpura fulminans 9.7
265 thrombosis 9.7
266 hyperlucent lung 9.7
267 corneal disease 9.7
268 xerophthalmia 9.7
269 dermatomyositis 9.7
270 thalassemia 9.7
271 mumps 9.7
272 parotitis 9.7
273 viral meningitis 9.7
274 pleural tuberculosis 9.7
275 open-angle glaucoma 9.7
276 chronic endophthalmitis 9.7
277 portal hypertension 9.7
278 malignant hypertension 9.7
279 hemiplegia 9.7
280 allergic conjunctivitis 9.7
281 heart disease 9.7
282 choroiditis 9.7
283 constrictive pericarditis 9.7
284 infant gynecomastia 9.7
285 portal vein thrombosis 9.7
286 lyme disease 9.7
287 choledocholithiasis 9.7
288 goiter 9.7
289 superficial keratitis 9.7
290 leukemia 9.7
291 hepatitis a 9.7
292 hepatic coma 9.7
293 acute kidney tubular necrosis 9.7
294 gynecomastia 9.7
295 telangiectasis 9.7
296 cicatricial ectropion 9.7
297 keratoconjunctivitis sicca 9.7
298 shipyard eye 9.7
299 porphyria 9.7
300 congenital dyserythropoietic anemia 9.7
301 pure red-cell aplasia 9.7
302 hepatic encephalopathy 9.7
303 urethritis 9.7
304 scleritis 9.7
305 hairy tongue 9.7
306 maxillary sinus cancer 9.7
307 facial paralysis 9.7
308 orbital cyst 9.7
309 neuroleptic malignant syndrome 9.7
310 reye syndrome 9.7
311 glossitis 9.7
312 cholera 9.7
313 urticaria 9.7
314 alcohol use disorder 9.7
315 mental depression 9.7
316 lymphadenitis 9.7
317 cystitis 9.7
318 heart septal defect 9.7
319 neovascular glaucoma 9.7
320 duodenal ulcer 9.7
321 pericarditis 9.7
322 status epilepticus 9.7
323 epilepsy 9.7
324 urethral stricture 9.7
325 atrial heart septal defect 9.7
326 malignant fibroxanthoma 9.7
327 melanoma 9.7
328 hyperuricemia 9.7
329 dysostosis 9.7
330 hyperinsulinism 9.7
331 hepatitis b 9.7
332 drug-induced hepatitis 9.7
333 autoimmune hepatitis 9.7
334 thrombocytosis 9.7
335 granulomatous hepatitis 9.7
336 transient cerebral ischemia 9.7
337 neonatal jaundice 9.7
338 blepharoconjunctivitis 9.7
339 retinal vascular disease 9.7
340 psychotic disorder 9.7
341 epidermolysis bullosa 9.7
342 contact dermatitis 9.7
343 endometriosis 9.7
344 adenocarcinoma 9.7
345 glioblastoma multiforme 9.7
346 astrocytoma 9.7
347 proctitis 9.7
348 acute porphyria 9.7
349 vaccinia 9.7
350 teratoma 9.7
351 benign epilepsy with centrotemporal spikes 9.7
352 gastric adenocarcinoma 9.7
353 cervical squamous cell carcinoma 9.7
354 arthropathy 9.7
355 merkel cell carcinoma 9.7
356 multidrug-resistant tuberculosis 9.7
357 secondary syphilis 9.7
358 syphilis 9.7
359 hyperglycemia 9.7
360 histiocytoma 9.7
361 folliculitis 9.7
362 fibrous histiocytoma 9.7
363 hypokalemia 9.7
364 cavernous hemangioma 9.7
365 benign ependymoma 9.7
366 urinary tract obstruction 9.7
367 eyelid disease 9.7
368 schizoaffective disorder 9.7
369 cellular ependymoma 9.7
370 severe combined immunodeficiency 9.7
371 juvenile pilocytic astrocytoma 9.7
372 t-cell leukemia 9.7
373 thyroiditis 9.7
374 end stage renal failure 9.7
375 chronic kidney disease 9.7
376 hyperthyroidism 9.7
377 peritonitis 9.7
378 appendicitis 9.7
379 bullous skin disease 9.7
380 herpes zoster 9.7
381 collagen disease 9.7
382 malignant hyperthermia 9.7
383 subacute delirium 9.7
384 myeloid leukemia 9.7
385 rubella 9.7
386 parasitic helminthiasis infectious disease 9.7
387 leishmaniasis 9.7
388 visceral leishmaniasis 9.7
389 priapism 9.7
390 viral infectious disease 9.7
391 iridocyclitis 9.7
392 epiglottitis 9.7
393 dacryoadenitis 9.7
394 neurofibroma 9.7
395 ulcerative stomatitis 9.7
396 renal tuberculosis 9.7
397 dacryocystitis 9.7
398 dacryocystocele 9.7
399 hemometra 9.7
400 hypoglycemia 9.7
401 acute articular rheumatism 9.7
402 acute graft versus host disease 9.7
403 adrenomyeloneuropathy 9.7
404 biliary tract cancer 9.7
405 febrile ulceronecrotic mucha-habermann disease 9.7
406 fournier gangrene 9.7
407 hydroa vacciniforme 9.7
408 meningococcemia 9.7
409 mycobacterium abscessus 9.7
410 oral lichen planus 9.7
411 parainfluenza virus type 3 9.7
412 pityriasis lichenoides 9.7
413 pityriasis lichenoides et varioliformis acuta 9.7
414 pseudobulbar affect 9.7
415 sinus cancer 9.7
416 splenomegaly 9.7
417 stenotrophomonas maltophilia infection 9.7
418 tuberculous meningitis 9.7
419 ulcerative proctitis 9.7
420 undifferentiated pleomorphic sarcoma 9.7
421 depression 9.7
422 febrile seizures 9.7
423 head injury 9.7
424 headache 9.7
425 subacute cutaneous lupus erythematosus 9.7
426 congenital amyoplasia 9.7
427 infective keratitis 9.7
428 epidermal disease 9.7
429 red cell aplasia 9.7

Graphical network of the top 20 diseases related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:



Diseases related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome

Symptoms & Phenotypes for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Human phenotypes related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

58 31 (showing 3, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 macrocephaly 58 31 hallmark (90%) Very frequent (99-80%) HP:0000256
2 macroorchidism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000053
3 intellectual disability, moderate 58 31 hallmark (90%) Very frequent (99-80%) HP:0002342

Drugs & Therapeutics for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Drugs for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 125, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Azithromycin Approved Phase 4 83905-01-5 55185 447043
3
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
4
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
5
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
6
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8 Ophthalmic Solutions Phase 4
9 Anti-Bacterial Agents Phase 4
10 Antimetabolites Phase 4
11 Analgesics Phase 4
12 Central Nervous System Depressants Phase 4
13 Analgesics, Opioid Phase 4
14 Anti-Anxiety Agents Phase 4
15 Tranquilizing Agents Phase 4
16 Psychotropic Drugs Phase 4
17 Antimanic Agents Phase 4
18 Excitatory Amino Acid Antagonists Phase 4
19 Anticonvulsants Phase 4
20 Excitatory Amino Acids Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Hypolipidemic Agents Phase 4
23 Lipid Regulating Agents Phase 4
24 Neurotransmitter Agents Phase 4
25 Autonomic Agents Phase 4
26 Adrenergic Antagonists Phase 4
27 Adrenergic beta-Antagonists Phase 4
28 Sympatholytics Phase 4
29 Adrenergic Agents Phase 4
30 Sodium Channel Blockers Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 Anti-Arrhythmia Agents Phase 4
33
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
34
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
35
Lesinurad Approved, Investigational Phase 3 878672-00-5 53465279
36
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
37
Etravirine Approved Phase 3 269055-15-4 193962
38
tannic acid Approved Phase 2, Phase 3 1401-55-4
39
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
40
Maraviroc Approved, Investigational Phase 2, Phase 3 376348-65-1 3002977
41
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
42
Etanercept Approved, Investigational Phase 3 185243-69-0
43
Coal tar Approved Phase 3 8007-45-2
44
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
45
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
46 Hypoglycemic Agents Phase 3
47 Antirheumatic Agents Phase 3
48 Renal Agents Phase 3
49 Cytochrome P-450 Enzyme Inhibitors Phase 3
50 Cytochrome P-450 CYP3A Inducers Phase 3
51 Reverse Transcriptase Inhibitors Phase 3
52 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
53 Anti-Infective Agents Phase 2, Phase 3
54 Anti-Retroviral Agents Phase 2, Phase 3
55 Antiviral Agents Phase 2, Phase 3
56 Anti-HIV Agents Phase 2, Phase 3
57 Immunologic Factors Phase 3
58 Pharmaceutical Solutions Phase 3
59 Cyclosporins Phase 3
60 Antifungal Agents Phase 3
61 Immunosuppressive Agents Phase 3
62 Calcineurin Inhibitors Phase 3
63 Anti-Inflammatory Agents, Non-Steroidal Phase 3
64 Emollients Phase 3
65 Antipsychotic Agents Phase 2, Phase 3
66 calcium channel blockers Phase 2, Phase 3
67 Calcium, Dietary Phase 2, Phase 3
68
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
69 Fibrin Tissue Adhesive Phase 1
70 Hemostatics Phase 1
71 Coagulants Phase 1
72 Anesthetics, Local Phase 1
73 Anesthetics Phase 1
74
Allopurinol Approved 315-30-0 2094
75
Metformin Approved 657-24-9 14219 4091
76
Glyburide Approved 10238-21-8 3488
77
Prednisolone Approved, Vet_approved 50-24-8 5755
78
Methylprednisolone Approved, Vet_approved 83-43-2 6741
79
Methylprednisolone hemisuccinate Approved 2921-57-5
80
Prednisolone phosphate Approved, Vet_approved 302-25-0
81 Prednisolone acetate Approved, Vet_approved 52-21-1
82
Methotrexate Approved 1959-05-2, 59-05-2 126941
83
leucovorin Approved 58-05-9 6006 143
84
Isotretinoin Approved 4759-48-2 5538 5282379
85
Eslicarbazepine acetate Approved 236395-14-5, 75970-99-9 123618
86
Carbamazepine Approved, Investigational 298-46-4 2554
87
Formaldehyde Approved, Vet_approved 50-00-0 712
88
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
89
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved 83-88-5 493570
90
Prednisolone hemisuccinate Experimental 2920-86-7
91 Free Radical Scavengers
92 Antioxidants
93 Liver Extracts
94 HIV Protease Inhibitors
95 Incretins
96
protease inhibitors
97 Dipeptidyl-Peptidase IV Inhibitors
98 Sitagliptin Phosphate
99 Protective Agents
100 Antiemetics
101 Methylprednisolone Acetate
102 Neuroprotective Agents
103 Antineoplastic Agents, Hormonal
104 Folic Acid Antagonists
105 Autoantibodies
106 Lubricant Eye Drops
107 Lycium
108 Goji
109 Chrysanthemum
110 Immunoglobulin A
111 Vitamins
112 Trace Elements
113 Micronutrients
114 Vitamin B Complex
115 Nutrients
116 Vitamin B2
117 Vitamin B9
118 Folate
119 Photosensitizing Agents
120 Dextrans
121 Antibodies
122 Immunoglobulins
123 Immunoglobulins, Intravenous
124 Rho(D) Immune Globulin
125 gamma-Globulins

Interventional clinical trials:

(showing 58, show less)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
3 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction Completed NCT01977937 Phase 4 Gabapentin 250mg/5mL NDC:59762-5025-01;Simple Syrup
4 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
5 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
6 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
8 Transdermal Lidocaine Patch for Post-Cesarean Pain Control for Women With Obesity: a Single-blind Randomized Controlled Trial Active, not recruiting NCT03810235 Phase 4 Transdermal Lidocaine Patch;Transdermal Hydrocolloid Placebo Patch
9 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
10 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
11 Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction Completed NCT01237600 Phase 2, Phase 3
12 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
13 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor Completed NCT01508702 Phase 3 lesinurad;Placebo
14 A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125. Completed NCT00792324 Phase 3 Etravirine;Efavirenz
15 Maraviroc to Augment Rehabilitation Outcomes After Stroke Recruiting NCT03172026 Phase 2, Phase 3 Maraviroc 300 mg;Placebo 300 mg
16 NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
17 Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
18 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
19 Evaluation the Effect of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Epithelium Healing (Phase I and II Clinical Trial) Completed NCT02746848 Phase 1, Phase 2
20 Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan Completed NCT00130013 Phase 1, Phase 2 Oral Amoxicillin
21 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
22 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
23 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
24 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
25 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
26 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction Completed NCT00344201 Phase 1
27 Topical Infliximab for the Treatment of Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
28 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Not yet recruiting NCT03878771 Phase 1 Dermovate cream in Orabase
29 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
30 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
31 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity. Unknown status NCT03166241
32 Drug Patch Tests, Enzyme-linked Immunosorbent Spot Assay (Elispot) and Lymphocyte Transformation Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs) Unknown status NCT03176342
33 The Use of Pentacam in Assessment of Corneal Changes After Pterygium Excision Unknown status NCT03304366
34 The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation Unknown status NCT00696982 sitagliptin;glibenclamide
35 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
36 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
37 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR) Completed NCT01276314 anti- TNF-a;Prednisolone
38 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
39 Urinary Ratio of the Coproporphyrins Isomers I and III and Its Relationships With Methotrexate Elimination in Patients With a Lymphoid Malignancy Completed NCT00822432
40 Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases Completed NCT00357071
41 Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye Completed NCT02219204
42 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Recruiting NCT02574988
43 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
44 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
45 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Recruiting NCT02795143 Isotretinoin
46 The Effects of Autologous Simple Limbal Epithelial Transplantation. Recruiting NCT04021875
47 Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study Recruiting NCT01611636
48 The Effects of Allogeneic Simple Limbal Epithelial Transplantation Recruiting NCT04021134
49 An Exploratory Case-Control Study of Genetic and Clinical Factors for Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
50 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study Recruiting NCT03184597
51 Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria (SALIENT-A) Recruiting NCT03445312
52 Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting Recruiting NCT03041883
53 Randomized Controlled Trial of Pharmacist-led Medication Review With Follow-up on Cardiovascular Older Adult Patients in Primary Care. POLARIS Active, not recruiting NCT03502109
54 An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients Available NCT02149732
55 A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT03585946 Site specific standard of care comparison
56 Hypo-pigmented Skin Lesions in Children : Dermoscopic Evaluation Not yet recruiting NCT04089475
57 Heidelberg Retina Tomograph (HRT) in Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals Not yet recruiting NCT04025801
58 Histologic Evaluation Comparing Power Settings in Radiofrequency Ablation on Eyelash Follicles Not yet recruiting NCT03947723

Search NIH Clinical Center for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome

Genetic Tests for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Anatomical Context for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

MalaCards organs/tissues related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

40
Skin, Eye, Liver, Testes, T Cells, Lung, Heart

Publications for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Articles related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

(showing 3965, show less)
# Title Authors PMID Year
1
Altered levels of complement components associated with non-immediate drug hypersensitivity reactions. 61
31795786 2020
2
Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. 61
31870573 2020
3
Long-term Progression of Ocular Surface Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
32028281 2020
4
Long-term and multiple hospital readmissions after discharge for Stevens-Johnson Syndrome and toxic epidermal necrolysis. 61
32017033 2020
5
A retrospective analysis of infections and antibiotic treatment in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
30095319 2020
6
Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. 61
30702955 2020
7
Searching for the Culprit Drugs for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis from a Nationwide Claim Database in Korea. 61
31614216 2020
8
Predictors of 30-day readmission in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cross-sectional database study. 61
31542405 2020
9
Stevens-Johnson syndrome and toxic epidermal necrolysis - retrospective review of cases in a high complexity hospital in Brazil. 61
31173347 2020
10
Management of immune checkpoint inhibitor-related dermatologic adverse events. 61
31814310 2020
11
The Clinical and Financial Impact of a Pharmacist-Driven Penicillin Skin Testing Program on Antimicrobial Stewardship Practices. 61
31983768 2020
12
Pattern-Specific Loss of Desmoplakin I and II Immunoreactivity in Erythema Multiforme and its Variants: A Possible Aid in Histologic Diagnosis. 61
31599750 2020
13
IP-10/CXCR3 axis is associated with HHV-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms. 61
32037509 2020
14
Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017. 61
31997613 2020
15
Comment on: "Microbial Keratitis in Stevens-Johnson Syndrome: A Prospective Study". 61
31658166 2020
16
Common and critical inflammatory dermatoses every pathologist should know. 61
31676787 2020
17
Validation of a clinical assessment tool for cicatrising conjunctivitis. 61
31693934 2020
18
Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption. 61
32002848 2020
19
Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies. 61
31931437 2020
20
Genetic contribution of ABCC2 to Dubin-Johnson syndrome and inherited cholestatic disorders. 61
31544333 2020
21
RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31954192 2020
22
Attenuation of Wnt/β-catenin signaling in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31929762 2020
23
Is there an association between Stevens-Johnson Syndrome and vaccination? A systematic review. 61
31713580 2020
24
Treatment for oral lesions in pediatric patients with Stevens-Johnson's syndrome: A case report and literature review. 61
31923328 2020
25
Genetic Variants Associated with T-Cell Mediated Cutaneous Adverse Drug Reactions: A Prisma-Compliant Systematic Review - an EAACI Position Paper. 61
31899808 2020
26
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication. 61
31912576 2020
27
Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017. 61
31323695 2020
28
Preparation of placental tissue transplants and their application in skin wound healing and chosen skin bullous diseases - Stevens-Johnson syndrome and toxic epidermal necrolysis treatment. 61
31943788 2020
29
Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. 61
31896765 2020
30
Controlling oral hemorrhages in Steven-Johnson syndrome/toxic epidermal necrolysis. 61
31279017 2020
31
Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting. 61
31608511 2020
32
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. 61
31951804 2020
33
Long-Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
31326519 2019
34
Laparoscopic cholecystectomy for cholecystolithiasis with Dubin-Johnson syndrome. 61
31832555 2019
35
Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. 61
30782092 2019
36
Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. 61
31898979 2019
37
Mutant GNLY is linked to Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31642954 2019
38
Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review. 61
31897340 2019
39
[Cutaneous lichen planus following Stevens-Johnson syndrome: Wolf's isotopic response]. 61
31627928 2019
40
Stevens-Johnson syndrome/toxic epidermal necrolysis: a chronic condition? 61
31853947 2019
41
Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. 61
31912590 2019
42
Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. 61
30908698 2019
43
The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients' lives: a Critically Appraised Topic. 61
31792924 2019
44
Depletion of regulatory FoxP3+ T cells in the pathogenesis of Stevens-Johnson syndrome induced by mogamulizumab. 61
31334834 2019
45
Evaluating Dry Eye and Meibomian Gland Dysfunction With Meibography in Patients With Stevens-Johnson Syndrome. 61
31205158 2019
46
Comment on 'Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children'. 61
31323139 2019
47
Timing of mucocutaneous symptoms and medication discontinuation in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. 61
31085266 2019
48
Contrast media and cutaneous reactions. Part 2: Delayed hypersensitivity reactions to iodinated contrast media. 61
31162717 2019
49
Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy. 61
31848905 2019
50
Glaucoma Management in Patients With Aniridia and Boston Type 1 Keratoprosthesis. 61
31247168 2019
51
Contribution to oral and maxillary surgery and surgical technique of osteo-odontokeratoprosthesis in Japan. 61
31378404 2019
52
Microbial Keratitis and Ocular Surface Disease: A 5-Year Study of the Microbiology, Risk Factors and Clinical Outcomes in Sydney, Australia. 61
31189397 2019
53
Could there be a relation between Steven-Johnson syndrome and ST-segment elevation myocardial infarction? 61
31748353 2019
54
Ocular manifestations in patients with Stevens-Johnson syndrome in Malawi-review of the literature illustrated by clinical cases. 61
31352606 2019
55
Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31466921 2019
56
Carbonic anhydrase inhibitor-induced Stevens-Johnson syndrome/toxic epidermal necrolysis leads to extensive cutaneous involvement. 61
31128378 2019
57
Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor. 61
31342541 2019
58
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms. 61
31706497 2019
59
Response: Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation - A retrospective chart review. 61
31712172 2019
60
Shaping specialist treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31742662 2019
61
Case of fertility treatment-induced Stevens-Johnson syndrome with a severe ocular complication. 61
31489686 2019
62
Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study. 61
31166019 2019
63
Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality. 61
30632424 2019
64
Highlights from the 2nd Biennial Stevens Johnson syndrome symposium 2019: SJS/TEN from Science to Translation. 61
31785388 2019
65
Stevens-Johnson syndrome/toxic epidermal necrolysis: treatment with low-dose corticosteroids, vitamin C and thiamine. 61
31678920 2019
66
Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. 61
31066027 2019
67
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 61
31387950 2019
68
Nursing problems in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome in a Dutch burn centre: A 30-year retrospective study. 61
31387802 2019
69
Two pediatric cases of influenza B-induced rash and mucositis: Stevens-Johnson syndrome or expansion of the Mycoplasma pneumoniae-induced rash with mucositis (MIRM) spectrum? 61
31576583 2019
70
Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review. 61
31436331 2019
71
Reply to "Response: Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation - a retrospective chart review." 61
31712175 2019
72
Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. 61
31100551 2019
73
Ocular Side Effects of Systemic Drugs Used in Dermatology. 61
31896837 2019
74
Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing. 61
31700100 2019
75
Drug allergy. 61
31690398 2019
76
CD39+ regulatory T cells modulate the immune response to carbamazepine in HLA-B*15:02 carriers. 61
31784043 2019
77
HLA-B*58:01 Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinol-A Canadian Missed Opportunity [Formula: see text]. 61
31378082 2019
78
Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. 61
31201937 2019
79
Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention. 61
31400461 2019
80
Temporo-Parietal Flap Incorporated Into a Modified Osteo-Odonto Keratoprostheses Protocol for Longevity of the Dental Lamina. 61
31876677 2019
81
Next generation sequencing reveals co-existence of hereditary spherocytosis and Dubin-Johnson syndrome in a Chinese gril: A case report. 61
31667183 2019
82
Corneal higher-order aberrations in Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31325631 2019
83
Clinical clues predictive of Stevens-Johnson syndrome as the cause of chronic cicatrising conjunctivitis. 61
31630093 2019
84
Clinical Outcome of Autologous Cultivated Oral Mucosal Epithelial Transplantation in Ocular Surface Reconstruction. 61
31356413 2019
85
Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review. 61
31651559 2019
86
A Study to Assess The Efficacy of Local Application of Oral Probiotic in Treating Recurrent Aphthous Ulcer and Oral Candidiasis. 61
31741944 2019
87
Long-term outcomes of donor eyes after conjunctival limbal autograft and allograft harvesting. 61
31564346 2019
88
Colonic Involvement of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Rare Cause of Gastrointestinal Bleeding. 61
31832469 2019
89
Contrast-induced generalized bullous fixed drug eruption resembling Stevens-Johnson syndrome. 61
31656435 2019
90
Upper airway involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31591001 2019
91
Stevens-Johnson syndrome complicated by fatal hemophagocytic lymphohistiocytosis. 61
31649973 2019
92
Authors' Reply to Cerejeira: "Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database". 61
31515698 2019
93
Comment on: "Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database". 61
31515699 2019
94
A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. 61
30908601 2019
95
[Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors]. 61
31650946 2019
96
[Mycoplasma pneumoniae-associated mucositis in a 17-year-old girl]. 61
31617477 2019
97
Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database. 61
31231846 2019
98
Recommendations for Prevention of Drug Re-Exposure in Toxic Epidermal Necrolysis 61
31603634 2019
99
Ophthalmic Manifestations of Mycoplasma-Induced Rash and Mucositis. 61
31246679 2019
100
Bullous fixed drug eruption: A potential diagnostic pitfall: a study of 18 cases. 61
31006486 2019
101
The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity. 61
31618895 2019
102
[Drug-induced toxic epidermal necrolysis with secondary aspergillus fumigatus infection: a case report]. 61
31624410 2019
103
A State-of-the-Art Review Highlighting Medical Overuse in Dermatology, 2017-2018: A Systematic Review. 61
31642872 2019
104
Effect of Scleral Lens Wear on Central Corneal Thickness and Intraocular Pressure in Patients With Ocular Surface Disease. 61
31652178 2019
105
Diagnostic Utility of Human Leukocyte Antigen B*15:02 Screening in Severe Carbamazepine Hypersensitivity Syndrome. 61
31736555 2019
106
Rowell Syndrome in Nigeria: Systemic Lupus Erythematosus Presenting as Recurrent Erythema Multiforme in a Young Woman. 61
31542069 2019
107
Skin scores: a review of clinical scoring systems in dermatology. 61
31675412 2019
108
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. 61
31327687 2019
109
[Acetaminophen induced Stevens-Johnson syndrome in a child]. 61
31530358 2019
110
Recurrent preseptal cellulitis in Boston keratoprosthesis type II implantation for ocular Stevens-Johnson syndrome. 61
31712017 2019
111
Predicting sepsis in Stevens-Johnson syndrome-toxic epidermal necrolysis: Should dermatologists be pro-procalcitonin? 61
31420075 2019
112
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. 61
30086678 2019
113
Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. 61
30809807 2019
114
Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. 61
30825193 2019
115
Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report. 61
31567395 2019
116
Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review. 61
31150704 2019
117
Stevens-Johnson syndrome and acute vanishing bile duct syndrome after the use of amoxicillin and naproxen in a child. 61
31448655 2019
118
Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype. 61
31308200 2019
119
Histomorphological Changes in Lachrymal Glands of Patients With Chronic Stevens-Johnson Syndrome. 61
31232745 2019
120
Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. 61
31594365 2019
121
Unusual oral findings of the toxic epidermal necrolysis in an HIV-infected patient: a case report. 61
31562853 2019
122
Sulfonamide Hypersensitivity: Fact and Fiction. 61
31495421 2019
123
Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients. 61
31195022 2019
124
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 61
31254013 2019
125
Pediatric SJS/TEN Subdued by a Combination of Dexamethasone, Cyclosporine, and Etanercept. 61
31478770 2019
126
Severe Cutaneous Adverse Reactions to Antiepileptic Drugs: A Nationwide Registry-Based Study in Korea. 61
31332981 2019
127
Triggers, clinical manifestations, and management of pediatric erythema multiforme: A systematic review. 61
31331726 2019
128
Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know. 61
30785787 2019
129
Stevens-Johnson Syndrome and Treatment With Clopidogrel. 61
30119955 2019
130
Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. 61
31616210 2019
131
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus. 61
29912772 2019
132
Microbial Keratitis in Stevens-Johnson Syndrome: A Prospective Study. 61
30998617 2019
133
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 61
30918988 2019
134
Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. 61
31434673 2019
135
Vulvovaginal Manifestations in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Prevention and Treatment. 61
31437544 2019
136
Incomplete Stevens-Johnson Syndrome Caused by Sulfonamide Antimicrobial Exposure. 61
31404173 2019
137
Altered retinoid metabolism gene expression in chronic Stevens-Johnson syndrome. 61
31023710 2019
138
Identification of drug-specific public TCR driving severe cutaneous adverse reactions. 61
31395875 2019
139
A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions. Part 2. 61
31241804 2019
140
Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database. 61
31041733 2019
141
Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-16: a four-source capture-recapture estimate. 61
31396952 2019
142
Making a diagnosis in severe cutaneous drug hypersensitivity reactions. 61
31247634 2019
143
Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. 61
31020549 2019
144
Drug hypersensitivity in HIV infection. 61
31145192 2019
145
Long-term effect of corneoscleral contact lenses on refractory ocular surface diseases. 61
30389416 2019
146
Erythema Multiforme: Recognition and Management. 61
31305041 2019
147
Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond. 61
31384575 2019
148
[Allergies to non-betalactam antibiotics: a challenge in practice]. 61
31282834 2019
149
[Warning symptoms skin: cutaneous manifestation of drug allergy]. 61
31282839 2019
150
Update on the role of impression cytology in ocular surface disease. 61
31572650 2019
151
Lip synechiae: A rare complication of azithromycin-associated Stevens-Johnson syndrome. 61
31798262 2019
152
Coxsackievirus B5-induced severe mucocutaneous reaction mimicking drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31062724 2019
153
Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
30872140 2019
154
Multistep Grading System for Evaluation of Chronic Ocular Sequelae in Patients With Stevens-Johnson Syndrome. 61
30731084 2019
155
Intravenous cyclosporine in treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series. 61
31070856 2019
156
Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. 61
30659711 2019
157
Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
30633324 2019
158
How different is Stevens-Johnson syndrome/toxic epidermal necrolysis in children? 61
31259411 2019
159
A case of recurrent Stevens-Johnson syndrome caused by nivolumab therapy. 61
31290394 2019
160
International and multidisciplinary scientific collaborations and networks are advancing knowledge about Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31259394 2019
161
The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
31365024 2019
162
The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-Reply. 61
31365027 2019
163
Direct in situ labeling of target drugs with a fluorophore probe to improve MALDI-MS detection sensitivity in micro-liter plasma. 61
31346224 2019
164
Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States. 61
31158306 2019
165
British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. 61
30829411 2019
166
Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
30613954 2019
167
Genetic testing for prevention of severe drug-induced skin rash. 61
31314143 2019
168
Individual- and hospital-level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012-2016. 61
31260078 2019
169
Characteristics of meibomian gland dysfunction in patients with Stevens-Johnson syndrome. 61
31261544 2019
170
Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. 61
30242287 2019
171
Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy. 61
30938822 2019
172
A modified technique for bedside amniotic membrane application to the eyelid margins for Stevens-Johnson syndrome. 61
31109496 2019
173
Presumed Sulfonamide-Associated Uveitis With Stevens-Johnson Syndrome in a Quarter Horse Mare. 61
31133310 2019
174
HLA-associated antiepileptic drug-induced cutaneous adverse reactions. 61
30895730 2019
175
Management of Acute Complications of Targeted Therapy in Patients With Cancer: A Review of Cases Managed in ICU. 61
30165779 2019
176
Severe Cutaneous Adverse Reactions during Tapering of High-Dose Systemic Steroid Therapy for Autoimmune Diseases: Implications for Non-HIV Immune Reconstitution Inflammatory Syndrome. 61
31275132 2019
177
[Anti-laminin 332 mucous membrane pemphigoid with irreversible ocular and tracheobronchial involvement : Delayed diagnosis of a severe autoimmune bullous disease]. 61
30963224 2019
178
Adult Coats' Disease, Dubin-Johnson Syndrome, and the Search for Targeted Therapies. 61
31100164 2019
179
Drug-induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. 61
30515930 2019
180
Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. 61
30282109 2019
181
Intravenous immunoglobulin treatment: Where do dermatologists stand? 61
30756448 2019
182
Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. 61
30430542 2019
183
Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. 61
30395917 2019
184
Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report. 61
31083216 2019
185
Prosthetic Replacement of the Ocular Surface Ecosystem Treatment for Ocular Surface Disease in Pediatric Patients With Stevens-Johnson Syndrome. 61
30664843 2019
186
Pancytopenia in a Patient with Stevens-Johnson Syndrome: A Case Report with Literature Review. 61
31355064 2019
187
Interventions for erythema multiforme: a systematic review. 61
30680804 2019
188
Analysis of Cutaneous Adverse Drug Reactions Reported at the Regional ADR Monitoring Center. 61
31148872 2019
189
Outpatient management and follow-up recommendations for adverse drug reactions: guidelines for posthospitalization care. 61
31233575 2019
190
Allopurinol-Induced Stevens-Johnson Syndrome. 61
30638600 2019
191
[A Case of Stevens-Johnson Syndrome Induced by Chemotherapy for Metastatic Colon Cancer]. 61
31164523 2019
192
Expression of prostaglandin E2 receptor 3 in the eyelid epidermis of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
31000507 2019
193
Topical moxifloxacin-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. 61
31036782 2019
194
Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. 61
30292922 2019
195
[Cutaneous Adverse Drug Reaction Caused by Antiepileptic Drug]. 61
30988229 2019
196
Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. 61
30840032 2019
197
Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population. 61
30705045 2019
198
Spontaneous Resolution of Cholesteatoma in a Patient on Long-Term Infliximab. 61
30632386 2019
199
Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database. 61
30689189 2019
200
An Update on Adverse Cutaneous Drug Reactions in HIV/AIDS. 61
31700852 2019
201
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. 61
30399387 2019
202
[Lamotrigine induced hypersensitivity syndrome in children: a case report]. 61
30996382 2019
203
Spontaneous cutaneous adverse drug reaction reports-An analysis of a 10-year dataset in Singapore. 61
30911397 2019
204
Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. 61
30612819 2019
205
Scoring systems for allergies and asthma in clinical research and practice. 61
30563587 2019
206
Stevens-Johnson syndrome. 61
30406877 2019
207
[Diagnosis of a patient with Dubin-Johnson syndrome by using next generation sequencing]. 61
30835355 2019
208
Novel complication of Flakka: Stevens-Johnson syndrome/Toxic epidermal necrolysis overlap. 61
30503281 2019
209
Corneal Limbal Stem Cell Deficiency in Children with Stevens-Johnson Syndrome. 61
30347185 2019
210
A Case of Stevens-Johnson Syndrome After Exposure to Valproic Acid. 61
30947405 2019
211
Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. 61
30968035 2019
212
Ciprofloxacin-Induced Bullae of the Lower Extremity: A Case of a Fixed Drug Reaction. 61
31135195 2019
213
The rash that presents as target lesions. 61
30981295 2019
214
Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-inflammatory Drugs. 61
30661313 2019
215
Severe Cutaneous Adverse Reactions in Korean Pediatric Patients: A Study From the Korea SCAR Registry. 61
30661316 2019
216
Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. 61
30826555 2019
217
Making Rash Decisions in Epilepsy: Evaluating Hypersensitivity Reactions to Anti-seizure Medications. 61
30955419 2019
218
A Case of Dubin-Johnson Syndrome in Pregnancy. 61
31016076 2019
219
Ocular Surface Reconstruction Using Circumferentially-trephined Autologous Oral Mucosal Graft Transplantation in Limbal Stem Cell Deficiency. 61
30746908 2019
220
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn's disease: Need for a multidisciplinary approach. 61
30541717 2019
221
Spectrum of gastrointestinal involvement in Stevens - Johnson syndrome. 61
30788030 2019
222
Fluoxetine-induced Stevens-Johnson syndrome and liver injury. 61
30296343 2019
223
Bronchiolitis Obliterans After Cefuroxime-Induced Stevens-Johnson Syndrome. 61
30737366 2019
224
Comprehensive assessment of T cell receptor β repertoire in Stevens-Johnson syndrome/toxic epidermal necrolysis patients using high-throughput sequencing. 61
30623817 2019
225
Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis. 61
30129156 2019
226
Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. 61
30298362 2019
227
Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea. 61
30666843 2019
228
Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. 61
30254188 2019
229
Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study. 61
30452692 2019
230
Dubin-Johnson syndrome in Tunisia: Spectrum of a rare disease. 61
30545689 2019
231
Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization. 61
30468876 2019
232
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview. 61
30058498 2019
233
[Clinical features and ABCC2 genotypic analysis of an infant with Dubin-Johnson syndrome]. 61
30675866 2019
234
Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma. 61
30729055 2019
235
Prognostication Using SCORTEN Severity of Illness Score in Patients With Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. 61
30273718 2019
236
Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
30830062 2019
237
Lacrimal passage irrigation in children with Stevens-Johnson syndrome or toxic epidermal necrolysis: a five-year retrospective study. 61
30658599 2019
238
Defining Regional Differences in Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety? 61
30120778 2019
239
Stevens-Johnson Syndrome complicated by obstructive uropathy, pneumothorax, and pneumomediastinum: a case report and literature review. 61
31205959 2019
240
Gene expression analysis of conjunctival epithelium of patients with Stevens-Johnson syndrome in the chronic stage. 61
31276031 2019
241
Complication during hospitalization of geronto-psychiatric patient for fatal Stevens-Johnson syndrome - a multidisciplinary approach. 61
31996000 2019
242
Ciprofloxacin-induced Stevens-Johnson Syndrome with Grapefruit Juice Consumption: A Case Report. 61
30868040 2019
243
A Review of the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
30702535 2019
244
Association of IKZF1 SNPs in cold medicine-related Stevens-Johnson syndrome in Thailand. 61
31768251 2019
245
Ocular and Mucocutaneous Sequelae among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo. 61
30838038 2019
246
Stevens-Johnson syndrome-like reaction without mucosal lesions associated with cyclophosphamide. 61
30504533 2019
247
Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
30285308 2019
248
Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of six cases. 61
31990471 2019
249
A Case Study of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis (SJS-TEN) Overlap in Mycoplasma pneumoniae-Associated Tracheobronchitis. 61
31275674 2019
250
A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. 61
29859332 2019
251
Anesthesia Considerations in Modified Osteo-odonto-keratoprosthesis. 61
29983007 2019
252
Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007⁻2018. 61
30658389 2019
253
[Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy]. 61
31787645 2019
254
An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions. 61
31692425 2019
255
Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. 61
31696806 2019
256
Empyema Necessitans due to Interruption of Antituberculosis Treatment. 61
31275673 2019
257
Adult-onset autoimmune-type enteropathy: potential relationship to an adverse drug reaction. 61
31875138 2019
258
Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Japanese individuals. 61
31666976 2019
259
Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa. 61
31308970 2019
260
The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. 61
29569740 2019
261
Development of an electronic medical record-based algorithm to identify patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan. 61
31408480 2019
262
Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens-Johnson syndrome. 61
29256167 2019
263
Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions. 61
31696807 2019
264
A Computational Platform and Guide for Acceleration of Novel Medicines and Personalized Medicine. 61
30848462 2019
265
Treatment of oral manifestations of toxic epidermal necrolysis with low-level laser therapy in a pediatric patient. 61
30474865 2019
266
Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients. 61
30726458 2019
267
Controversies in drug allergy: Testing for delayed reactions. 61
30573342 2019
268
[Recalcitrant cicatrizing conjunctivitis. Treatment of nine patients with rituximab]. 61
31487253 2019
269
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study. 61
30112729 2019
270
Role of in vivo and in vitro Tests in the Diagnosis of Severe Cutaneous Adverse Reactions (SCAR) to Drug. 61
31696801 2019
271
Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea. 61
29466850 2019
272
Ocular Surface Microbial Flora in Patients with Chronic Limbal Stem Cell Deficiency Undergoing Cultivated Oral Mucosal Epithelial Transplantation. 61
31114120 2019
273
Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. 61
29800753 2019
274
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. 61
30509740 2019
275
Report: A case report on Nevirapine induced exfoliative dermatitis. 61
30772813 2019
276
Use of Cyclosporine for the treatment of Steven Johnson Syndrome/ Toxic Epidermal Necrolysis. 61
30630021 2019
277
Skin Allergy to Azole Antifungal Agents for Systemic Use: A Review of the Literature. 61
31538908 2019
278
Early Biomarkers for Severe Drug Hypersensitivity Reactions. 61
31696802 2019
279
Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics. 61
31089385 2019
280
Oxcarbazepine-Induced Stevens-Johnson Syndrome. 61
30605267 2018
281
An Interesting Case of Carbamazepine-Induced Stevens-Johnson Syndrome. 61
30535610 2018
282
[Clinical and pathological features of inherited metabolic liver disease in adults]. 61
30669779 2018
283
Major Histocompatibility Complex and Psoriasis. 61
30471757 2018
284
Silver absorption in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis treated with silver-impregnated dressings. A case series. 61
29893032 2018
285
Minimal clinically important differences for measures of treatment efficacy in Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
29890189 2018
286
Stevens Johnson Syndrome with Vaginal Pain and Lesions as Initial Presentation. 61
30573724 2018
287
Stevens - Johnson syndrome (SJS) following Murunga leaf (Moringa oleifera) consumption 61
30669215 2018
288
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report. 61
30301570 2018
289
Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System. 61
30395352 2018
290
Risks associated with lamotrigine prescription: a review and personal observations. 61
29480028 2018
291
Twelve years of Lyell's Syndrome in the burn unit of São João Hospital Centre. 61
30983925 2018
292
Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature. 61
30169429 2018
293
Infectious Keratitis After Ocular Surface Stem Cell Transplantation. 61
30004958 2018
294
Oral isotretinoin for acne. 61
30484286 2018
295
Topical Treatment of Persistent Epithelial Defects with a Matrix Regenerating Agent. 61
30312119 2018
296
Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient. 61
29885481 2018
297
Novel compound heterozygous ABCC2 variants in patients with Dubin-Johnson syndrome and intrahepatic cholestasis of pregnancy. 61
30092126 2018
298
Mutation analysis of the ABCC2 gene in Chinese patients with Dubin-Johnson syndrome. 61
30344695 2018
299
Topical mesalazine as a cause of Stevens-Johnson syndrome. 61
29931986 2018
300
Results of Detailed Investigations Into Stevens-Johnson Syndrome With Severe Ocular Complications. 61
30481825 2018
301
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. 61
29758282 2018
302
Chemistry-Wide Association Studies (CWAS): A Novel Framework for Identifying and Interpreting Structure-Activity Relationships. 61
30376324 2018
303
High-risk drug rashes. 61
29803714 2018
304
Propranolol eye drops in patients with corneal neovascularization. 61
30407290 2018
305
Safety assessment of omeprazole use: a review. 61
30892487 2018
306
Outcomes of the Boston Type I Keratoprosthesis as the Primary Penetrating Corneal Procedure. 61
30157053 2018
307
Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. 61
30112775 2018
308
Severe Dry Eye With Combined Mechanisms is Involved in the Ocular Sequelae of SJS/TEN at the Chronic Stage. 61
30481810 2018
309
Methotrexate-Induced Toxic Epidermal Necrolysis: A Rare Case Report and Review of Literature. 61
30405287 2018
310
Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. 61
29985833 2018
311
Microbial keratitis in Stevens-Johnson syndrome: Clinical and microbiological profile. 61
29981457 2018
312
Reply to: "Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need". 61
29913260 2018
313
Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need. 61
29913262 2018
314
Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. 61